Actively Recruiting
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Led by Fudan University · Updated on 2024-05-02
354
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor +/- chemotherapy alone. The primary end point was progression-free survival (PFS). The secondary end points included overall survival, side effects and local control.
CONDITIONS
Official Title
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- ECOG performance status 0 or 1
- Diagnosed with esophageal squamous cell carcinoma
- Have genuine oligometastatic disease defined by ASTRO/ESTRO with 4 or fewer distant metastases
- Have 3 or fewer metastatic lesions within a single organ
- Each metastatic lesion measures 5 cm or less in diameter
- At least one metastasis is confirmed by pathology
You will not qualify if you...
- History of widespread metastases or induced oligometastatic disease as defined by ASTRO/ESTRO
- Esophageal perforation or hemorrhage
- Disease progression after PD-1 inhibitor treatment
- Recurrence of cancer within previously treated area
- Unable to tolerate chemotherapy or immunotherapy
- Lung radiation exposure (V20) greater than 25%
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai cancer center
Shanghai, China
Actively Recruiting
Research Team
Q
Qi Liu, MD
CONTACT
K
Kuaile Zhao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here